Article
Repurposing antiparasitic antimonials to noncovalently rescue temperature-sensitive p53 mutations.
Cell reports - 12 Apr 2022
Tang Yigang, Song Huaxin, Wang Zhengyuan, Xiao Shujun, Xiang Xinrong, Zhan Huien, Wu Lili, Wu Jiale, Xing Yangfei, Tan Yun, Liang Ying, Yan Ni, Li Yuntong, Li Jiabing, Wu Jiaqi, Zheng Derun, Jia Yunchuan, Chen Zhiming, Li Yunqi, Zhang Qianqian, Zhang Jianming, Zeng Hui, Tao Wei, Liu Feng, Wu Yu, Lu Min
Abstract excerpt
The tumor suppressor p53 is inactivated by over hundreds of heterogenous mutations in cancer. Here, we purposefully selected phenotypically reversible temperature-sensitive (TS) p53 mutations for pharmacological rescue with thermostability as the compound-screening readout. This rational screening identified antiparasitic drug potassium antimony tartrate (PAT) as an agent that can thermostabilize the...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.